What is Zacks Research’s Forecast for IRWD FY2025 Earnings?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Analysts at Zacks Research dropped their FY2025 earnings estimates for shares of Ironwood Pharmaceuticals in a report issued on Monday, October 14th. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings per share of $0.19 for the year, down from their previous forecast of $0.32. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.24 per share.

Several other research firms have also recently commented on IRWD. Leerink Partners began coverage on Ironwood Pharmaceuticals in a report on Monday, September 9th. They issued a “market perform” rating and a $5.00 price target for the company. Wells Fargo & Company cut their target price on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, August 9th. StockNews.com raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 16th. Craig Hallum reduced their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 9th. Finally, Capital One Financial lowered shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $12.00 to $4.00 in a research report on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $12.17.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD opened at $4.44 on Thursday. The company has a 50-day simple moving average of $4.45 and a 200-day simple moving average of $6.03. Ironwood Pharmaceuticals has a 52 week low of $3.79 and a 52 week high of $15.70. The firm has a market capitalization of $694.99 million, a P/E ratio of -0.65 and a beta of 0.48.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several institutional investors have recently bought and sold shares of IRWD. CWM LLC increased its stake in shares of Ironwood Pharmaceuticals by 55.1% in the second quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 2,345 shares in the last quarter. PNC Financial Services Group Inc. increased its position in Ironwood Pharmaceuticals by 152.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 2,645 shares in the last quarter. Diversified Trust Co bought a new position in shares of Ironwood Pharmaceuticals in the third quarter worth about $52,000. GAMMA Investing LLC lifted its position in shares of Ironwood Pharmaceuticals by 344.1% during the second quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 8,156 shares in the last quarter. Finally, First Dallas Securities Inc. bought a new stake in shares of Ironwood Pharmaceuticals during the second quarter valued at approximately $73,000.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, insider Minardo John sold 9,910 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $4.27, for a total transaction of $42,315.70. Following the sale, the insider now directly owns 284,661 shares of the company’s stock, valued at approximately $1,215,502.47. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 12.90% of the stock is currently owned by corporate insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.